Welcome to our dedicated page for Paragon 28 news (Ticker: FNA), a resource for investors and traders seeking the latest updates and insights on Paragon 28 stock.
Paragon 28, Inc. (FNA) is a pioneering medical devices company focused exclusively on the orthopedic foot and ankle market. Founded in 2010, the name ‘Paragon 28’ signifies its dedication to this niche, with ‘28’ representing the number of bones in the human foot. The company was started as a small, family-based business and, while it has seen significant growth, it holds steadfast to its original core values.
Paragon 28 is dedicated to advancing the science behind foot and ankle surgery through innovative and high-quality solutions. The company collaborates with global thought leaders to blend various surgical philosophies, resulting in biomechanically and clinically relevant surgical solutions. Their comprehensive product lineup includes plates and plating systems, screws, staples, and nails designed for all major foot and ankle procedures such as ankle, Charcot, fracture fixation, hallux valgus, hammertoe, and flat foot corrections.
With nearly 80 product systems, Paragon 28 aims to meet the specific needs of each patient and procedure, ensuring precise and effective outcomes. The company is also committed to providing excellent customer service through a dedicated and highly trained distribution network, primarily targeting the foot and ankle market.
Operating efficiently to meet the demands of pricing pressures and reimbursement challenges, Paragon 28 generates the majority of its revenue from the United States. The company's relentless focus on innovation and service has led to significant milestones, making it a trusted name in the foot and ankle surgical space.
Paragon 28, Inc. (NYSE: FNA), a leader in the foot and ankle orthopedic market, will release its financial results for Q4 and FY 2022 after market close on March 2, 2023. A conference call will follow at 4:30 p.m. ET, available for investors by dialing (844-200-6205) domestically and (929-526-1599) internationally, with conference ID 798665. The call will also be accessible via webcast on the company's investor website. Established in Englewood, Colo., Paragon 28 focuses on innovative orthopedic solutions aimed at improving patient outcomes in foot and ankle conditions.
Paragon 28, Inc. (NYSE: FNA) announced a public offering of 6,500,000 shares of its common stock, priced at
Paragon 28, Inc. (NYSE: FNA) has announced a proposed underwritten public offering of 6,500,000 shares of its common stock, with 3,750,000 shares from Paragon and 2,750,000 shares from selling securityholders. Additionally, underwriters may purchase 975,000 shares under a 30-day option. Proceeds will primarily support working capital and corporate needs, with possibilities for product investments. However, Paragon will not benefit from the sale of shares by selling securityholders. BofA Securities and Piper Sandler & Co. lead the offering, which is subject to market conditions.
Paragon 28, Inc. (NYSE: FNA) has announced its preliminary unaudited revenue for Q4 and the full year of 2022. Q4 revenue is projected between $51.2 million and $51.5 million, marking a growth of approximately 20% year-over-year, despite foreign currency challenges impacting growth by 1.6 percentage points. For the full year, net revenue is expected to be between $181.0 million and $181.3 million, reflecting a growth of about 23.0% compared to 2021. The company plans to release its 2023 financial guidance later in the quarter.
Paragon 28, Inc. (NYSE: FNA), a leader in the medical device sector focusing on the foot and ankle orthopedic market, will have CEO Albert DaCosta and CFO Steve Deitsch participate in a fireside chat at the 34th Annual Piper Sandler Healthcare Conference. This event is scheduled for Thursday, December 1, 2022, at 8:30 a.m. Eastern Time. A live webcast and archived recording will be accessible on the company's investor relations website.
Paragon 28 is committed to improving patient outcomes through innovative orthopedic solutions.
Paragon 28, Inc. (NYSE: FNA) reported a record net revenue of $46.0 million for Q3 2022, marking a 28% increase from the previous year. U.S. revenue reached $40.0 million, up 25%, driven by improved sales productivity and new product launches. International revenue also set a record at $6.0 million, growing 52%. Despite foreign currency headwinds impacting revenue by $0.8 million, the company raised its 2022 net revenue guidance to $179.5 million, reflecting a 22% growth. However, net loss expanded to $9.7 million, contributing to a negative adjusted EBITDA of $2.7 million.
Paragon 28, Inc. (NYSE: FNA), a leading medical device company focused on foot and ankle orthopedics, will release its third-quarter 2022 financial results on November 10, 2022, after market close. A conference call will follow at 4:30 p.m. ET to discuss the results. Investors can participate by dialing (844-200-6205) or (929-526-1599) internationally, using conference ID: 703484. The call will be available for replay for 90 days on the company’s website.
Paragon 28, Inc. (NYSE: FNA), a leading medical device company focused on foot and ankle orthopedics, announced its participation in the Morgan Stanley 20th Annual Global Healthcare Conference. The company's Chairman and CEO, Albert DaCosta, along with CFO Steve Deitsch, will present a fireside chat on September 13, 2022, at 3:30 p.m. ET. A live webcast will be accessible through the investor relations section of their website at ir.paragon28.com.
Paragon 28, Inc. (NYSE: FNA) reported a 19% growth in net revenue for Q2 2022, totaling $42.5 million, driven by increased productivity and new product launches. U.S. revenue was $36.8 million with a similar 19% increase. Internationally, the company achieved record revenue of $5.7 million, up 20%. Despite this growth, Paragon reported a net loss of $9.6 million and raised its 2022 revenue guidance to $176 million. Operating expenses surged to $43.9 million, influenced by one-time costs related to a new SAP launch.
Paragon 28, Inc. (NYSE: FNA), a leader in medical devices for foot and ankle orthopedics, announced that its Chairman and CEO, Albert DaCosta, along with CFO Steve Deitsch, will present at The Canaccord Genuity 42nd Annual Growth Conference in Boston. The fireside chat is scheduled for August 11, 2022, at 1:00 PM Eastern Time. Interested investors can access the live webcast and archived recording via the Company's investor relations website.
FAQ
What is the current stock price of Paragon 28 (FNA)?
What is the market cap of Paragon 28 (FNA)?
What does Paragon 28, Inc. specialize in?
When was Paragon 28, Inc. founded?
What is the significance of the name 'Paragon 28'?
What types of products does Paragon 28 offer?
How many product systems does Paragon 28 have?
Where does Paragon 28 generate the majority of its revenue?
What is Paragon 28’s approach to innovation?
What is Paragon 28’s commitment to customer service?
How does Paragon 28 address pricing pressures and reimbursement challenges?
What recent achievements has Paragon 28 made?
